WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522412

CAS#: 136451-58-6

Description: BMY-42393 is orally active and selective platelet aggregation inhibitor. BMY-42393 is also a prostacyclin partial agonist that inhibited ADP, collagen and thrombin-induced platelet aggregation (IC50 range 0.3 - 2.0 microM). BMY-42393 stimulated platelet adenylate cyclase activity (EC50 = 25 nM). Platelets treated with BMY 42393 showed an elevation of cAMP levels and activation of cAMP-dependent protein kinase. BMY 42393 also inhibited thrombin-induced elevation of intracellular free calcium. BMY 42393 competed for radiolabeled iloprost and PGE1 binding to platelet membranes (IC50; 170 nM and 130 nM, respectively).

Chemical Structure

CAS# 136451-58-6

Theoretical Analysis

MedKoo Cat#: 522412
Name: BMY-42393
CAS#: 136451-58-6
Chemical Formula: C26H18N2O5
Exact Mass: 438.12157
Molecular Weight: 438.44
Elemental Analysis: C, 71.23; H, 4.14; N, 6.39; O, 18.25

Price and Availability

Size Price Availability Quantity
Bulk inquiry

Synonym: BMY-42393; BMY 42393; BMY42393.

IUPAC/Chemical Name: 2-(3-(4,5-diphenyl-[2,4'-bioxazol]-5'-yl)phenoxy)acetic acid


InChi Code: InChI=1S/C26H18N2O5/c29-21(30)15-31-20-13-7-12-19(14-20)24-23(27-16-32-24)26-28-22(17-8-3-1-4-9-17)25(33-26)18-10-5-2-6-11-18/h1-14,16H,15H2,(H,29,30)

SMILES Code: O=C(O)COC1=CC=CC(C2=C(C3=NC(C4=CC=CC=C4)=C(C5=CC=CC=C5)O3)N=CO2)=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 438.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Chow KB, Wong YH, Wise H. Prostacyclin receptor-independent inhibition of phospholipase C activity by non-prostanoid prostacyclin mimetics. Br J Pharmacol. 2001 Dec;134(7):1375-84. PubMed PMID: 11724742; PubMed Central PMCID: PMC1573079.

2: Kam Y, Chow KB, Wise H. Factors affecting prostacyclin receptor agonist efficacy in different cell types. Cell Signal. 2001 Nov;13(11):841-7. PubMed PMID: 11583920.

3: Rudd JA, Qian Ym, Tsui KK, Jones RL. Non-prostanoid prostacyclin mimetics as neuronal stimulants in the rat: comparison of vagus nerve and NANC innervation of the colon. Br J Pharmacol. 2000 Feb;129(4):782-90. PubMed PMID: 10683203; PubMed Central PMCID: PMC1571884.

4: Jones RL, Qian YM, Wise H, Wong HN, Lam WL, Chan HW, Yim AP, Ho JK. Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery. J Cardiovasc Pharmacol. 1997 Apr;29(4):525-35. PubMed PMID: 9156364.

5: Wise H, Chow KB. The effect of non-prostanoid prostacyclin mimetics on cyclic AMP production by neuronal SK-N-SH cells. Adv Exp Med Biol. 1997;433:197-200. PubMed PMID: 9561134.

6: Wise H. The effect of prostacyclin mimetics on neutrophil function. Adv Exp Med Biol. 1997;407:261-4. PubMed PMID: 9321962.

7: Seiler SM, Brassard CL, Federici ME, Romine J, Meanwell NA. [3-[4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding. Prostaglandins. 1997 Jan;53(1):21-35. PubMed PMID: 9068064.

8: Wise H. The inhibitory effects of non-prostanoid prostacyclin mimetics on rat neutrophil function. Prostaglandins Leukot Essent Fatty Acids. 1996 May;54(5):351-60. PubMed PMID: 8832764.

9: Wise H, Qian YM, Jones RL. A study of prostacyclin mimetics distinguishes neuronal from neutrophil IP receptors. Eur J Pharmacol. 1995 May 24;278(3):265-9. PubMed PMID: 7589166.

10: Seiler SM, Buchanan JO, Schumacher WA, Zavoico GB, Gamberdella M, Fleming JS, Meanwell NA. 2-[3-[2-(4,5-diphenyl-2-oxazolyl) ethyl] phenoxy] acetic acid (BMY 42393): 2). Oral activity and efficacy in animal models of arterial thrombosis. Thromb Res. 1994 Apr 15;74(2):125-33. PubMed PMID: 8029813.

11: Seiler SM, Brassard CL, Federici ME, Buchanan JO, Zavoico GB, Fleming JS, Meanwell NA. 2-[3-[2-(4,5-Diphenyl-2-oxazolyl) ethyl] phenoxy] acetic acid (BMY 42393): a new, structurally-novel prostacyclin partial agonist: 1). Inhibition of platelet aggregation and mechanism of action. Thromb Res. 1994 Apr 15;74(2):115-23. PubMed PMID: 8029812.

12: Meanwell NA, Rosenfeld MJ, Trehan AK, Wright JJ, Brassard CL, Buchanan JO, Federici ME, Fleming JS, Gamberdella M, Hartl KS, et al. Non-prostanoid prostacyclin mimetics. 6. Derivatives of 2-[3-[2-(4,5-Diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid modified beta-to the oxazole ring. Drug Des Discov. 1994 Jan;11(1):73-89. PubMed PMID: 7520762.

13: Kowala MC, Mazzucco CE, Hartl KS, Seiler SM, Warr GA, Abid S, Grove RI. Prostacyclin agonists reduce early atherosclerosis in hyperlipidemic hamsters. Octimibate and BMY 42393 suppress monocyte chemotaxis, macrophage cholesteryl ester accumulation, scavenger receptor activity, and tumor necrosis factor production. Arterioscler Thromb. 1993 Mar;13(3):435-44. PubMed PMID: 8443148.

14: Meanwell NA, Rosenfeld MJ, Trehan AK, Wright JJ, Brassard CL, Buchanan JO, Federici ME, Fleming JS, Gamberdella M, Zavoico GB, et al. Nonprostanoid prostacyclin mimetics. 2. 4,5-Diphenyloxazole derivatives. J Med Chem. 1992 Sep 18;35(19):3483-97. PubMed PMID: 1404230.